Journal Mobile Options
Table of Contents
Vol. 17, No. 4, 2004
Issue release date: June 2004
Dement Geriatr Cogn Disord 2004;17:355–359

Frontotemporal Dementia: A Randomised, Controlled Trial with Trazodone

Lebert F. · Stekke W. · Hasenbroekx C. · Pasquier F.
aMemory Clinic, Lille University Hospital, Lille, France; bPharmacia Laboratory, Diegem, cDepartment of Neurology, Heilig Hart Ziekenhuis, Roeselare, Belgium

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Behavioural troubles due to frontotemporal dementia (FTD) are difficult to treat. The serotonergic system is associated with frontal lobes, the degeneration of which contributes to FTD. Trazodone increases the extracellular 5-HT levels in the frontal cortex. In a randomised, double-blind, placebo-controlled cross-over study, we investigated the effect of trazodone. There was a significant decrease in the Neuropsychiatry Inventory (NPI) total score with trazodone (p = 0.028) in the 26 evaluable patients. A decrease of more than 50% in the NPI score was observed in 10 patients with trazodone. This improvement was mainly based on the improvement of 4 items of the scale (irritability, agitation, depressive symptoms and eating disorders). The Mini-Mental State Examination was not modified and trazodone was well tolerated. Results of this first placebo-controlled trial suggest that trazodone is an effective treatment for the behavioural symptoms of FTD.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Grossman MA: Multidisciplinary approach to Pick’s disease and frontotemporal dementia. Neurology 2001;56:1S–2S.
  2. Sjögren M, Minthon L, Passant U, et al: Decreased monoamine metabolites in frontotemporal dementia and Alzheimer’s disease. Neurobiol Aging 1998;19:379–384.
  3. Sparks DL, Markesbery WR: Altered serotonergic and cholinergic synaptic markers in Pick’s disease. Arch Neurol 1991;48:796–799.
  4. Procter AW, Qurne M, Francis PT: Neurochemical features of frontotemporal dementia. Dement Geriatr Cogn Disord 1999;10(suppl 1):80–84.
  5. Swartz JR, Miller BL, Lesser IM, Darby AL: Frontotemporal dementia: Treatment response to serotonin selective reuptake inhibitors. J Clin Psychiatry 1997;58:212–216.
  6. Lebert F, Pasquier F, Petit H: Trazodone in the treatment of behavior in frontotemporal dementia. Hum Psychopharmacol Clin Exp 1999;14:279–281.
  7. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gorbein J: The neuropsychiatric inventory. Neurology 1994;44:2308–2314.
  8. Lebert F, Pasquier F, Souliez L, Petit H: Frontotemporal behavioral scale. Alzheimer Dis Assoc Disord 1998;12:335–339.
  9. Mattis S: Mental status examination for organic mental syndrome in the elderly patients; in Bellak L, Karasu TB (eds): Geriatric Psychiatry. New York, Grune & Stratton, 1986, pp 77–121.
  10. Folstein MF, Folstein SE, McHugh PR: ‘Mini-mental state’: A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189–198.
  11. Teri L, Logsdon RG, Peskind E, et al: Treatment of agitation in AD: A randomized, placebo-controlled clinical trial. Neurology 2000;55:1271–1278.
  12. Pasquier F, Fukui I, Sarazin M, et al: Laboratory investigations and treatment. Ann Neurol 2003;53(suppl 5):S32–S35.
  13. Chow TW: Frontotemporal dementias: Clinical features and management. Semin Clin Neuropsychiatry 2003, 8:58–70.
  14. Moretti R, Torre P, Antonello RM, Cazzato G, Bava A: Frontotemporal dementia: Paroxetine as a possible treatment of behavior symptoms. Eur Neurol 2003;49:13–19.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50